This program pursues a set of overarching scientific goals: (1) to identify environmental, biological, psychosocial, epigenetic, and genetic factors that influence cancer risk, occurrence, and progression through basic, genetic and epigenetic, and epidemiologic research; (2) to clarify the impact of cancer and cancer treatment through outcomes research; (3) to develop, implement, evaluate, and disseminate educational, behavioral, and psychosocial interventions aimed at preventing cancer, improving eariy detection, enhancing symptom management, improving health and quality of life for cancer survivors, caregivers, and families, and advancing the science to improve palliative and end-of-life care; and (4) to advance cancer prevention, detection, and control within the broader contexts of institution and society through quality, economic, and policy studies. Program activities target five prioritized themes: disparities, tobacco cessation, obesity and nutrition, geriatric oncology, and survivorship (including symptom control and palliative care). Structurally, research within three main program sections - Epidemiology and Genetics Research, Behavioral Sciences Research, Applied Research - address these cross-cutting themes. Leading-edge research is underway in each section; examples are studies of epigenetic markers of cancer risk (Epidemiology and Genetics Research), neural correlates of nicotine addiction (Behavioral Sciences Research), and impact of Medicare policy change on access to chemotherapy (Applied Research). The program is integrally involved in forerunning national and institutional initiatives. Among these directions are: personalized medicine; patientreported outcomes; survivorship care, including palliative and end-of-life care; increasing minority enrollment in clinical trials, incorporation of bioinformatics and complex data functions across the full research spectrum; development of quality assessment approaches; and creation of a learning healthcare environment. This program currently comprises 46 Duke Comprehensive Cancer Institute members across 21 departments, divisions, schools and institutes. Grant funding has increased since our last submission, from $13,177,478 direct funding in 2004 to $21,317,489 in 2008 (11% NCI funding, 40% NIH funding). During the recent fiveyear period, we have published over 1,100 peer-reviewed papers; 152 papers (13%) demonstrate intraprogrammatic collaboration and 162 papers (14%) demonstrate inter-programmatic collaborations.

Public Health Relevance

Despite a proliferation of novel treatment approaches, cancer continues to pose a major public health threat. Improved prevention, through higher screening rates and new strategies enabling eariier detection, will help reduce cancer incidence. For cancer patients at all stages, better symptom management - employing pharmaceutical, cognitive-behavioral, communication, and psychosocial approaches - will minimize suffering and optimize quality of life. Applied research will support the translation of epidemiologic, genetic, and behavioral research findings to improve outcomes, and the quality and cost effectiveness of cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA014236-38S1
Application #
8532213
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
38
Fiscal Year
2012
Total Cost
$2,500
Indirect Cost
$908
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Galaz-Montoya, Monica; Wright, Sara J; Rodriguez, Gustavo J et al. (2017) ?2-Adrenergic receptor activation mobilizes intracellular calcium via a non-canonical cAMP-independent signaling pathway. J Biol Chem 292:9967-9974
Lanier, Megan L; Park, Hyeri; Mukherjee, Paramita et al. (2017) Formal Synthesis of (+)-Laurencin by Gold(I)-Catalyzed Intramolecular Dehydrative Alkoxylation. Chemistry 23:7180-7184
Shi, Qiong; Liu, Hongliang; Han, Peng et al. (2017) Genetic Variants in WNT2B and BTRC Predict Melanoma Survival. J Invest Dermatol 137:1749-1756
Woyach, Jennifer A; Ruppert, Amy S; Guinn, Daphne et al. (2017) BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. J Clin Oncol 35:1437-1443
Wang, Yanru; Freedman, Jennifer A; Liu, Hongliang et al. (2017) Associations between RNA splicing regulatory variants of stemness-related genes and racial disparities in susceptibility to prostate cancer. Int J Cancer 141:731-743
Fayanju, Oluwadamilola M; Hall, Carolyn S; Bauldry, Jessica Bowman et al. (2017) Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214:666-671
Leu, David; Spasojevic, Ivan; Nguyen, Huy et al. (2017) CNS bioavailability and radiation protection of normal hippocampal neurogenesis by a lipophilic Mn porphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5. Redox Biol 12:864-871
Sauer, Scott J; Tarpley, Michael; Shah, Imran et al. (2017) Bisphenol A activates EGFR and ERK promoting proliferation, tumor spheroid formation and resistance to EGFR pathway inhibition in estrogen receptor-negative inflammatory breast cancer cells. Carcinogenesis 38:252-260
Pan, Yongchu; Liu, Hongliang; Wang, Yanru et al. (2017) Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. Sci Rep 7:44634
Yin, Jieyun; Liu, Hongliang; Liu, Zhensheng et al. (2017) Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. Mol Carcinog 56:1663-1672

Showing the most recent 10 out of 480 publications